EGFR and breast carcinoma: Several phase II clinical trials using an EGFR inhibitor (gefitinib or erlotinib) as monotherapy on advanced breast cancers (not necessarily TNBC) found minimal benefits from treatment, reporting PR rates of 0–3% and no reported CRs [103,104,105].